section name header

Pronunciation

tye-roe-FYE-ban

Classifications

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: glycoprotein iib iiia inhibitors

Indications

High Alert


Action

  • Decreases platelet aggregation by reversibly antagonizing the binding of fibrinogen to the glycoprotein IIb/IIIa binding site on platelet surfaces.
Therapeutic effects:
  • Inhibition of platelet aggregation resulting in decreased incidence of new MI, death, or refractory ischemia with the need for repeat cardiac procedures.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Excreted mostly unchanged by the kidneys (65%); 25% excreted unchanged in feces.

Half-Life: 2 hr.

Time/Action Profile

(effects on platelet function)

ROUTEONSETPEAKDURATION
IVrapid30 minbrief



>90% inhibition of platelet aggregation at end of initial 30-min infusion.

Inhibition is reversible following cessation of infusion.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Noted for patients receiving heparin and aspirin in addition to tirofiban

CV: bradycardia, coronary dissection, edema, vasovagal reaction

Derm: hives, rash, sweating

GI: nausea

Hemat: BLEEDING, thrombocytopenia

MS: leg pain

Neuro: headache, dizziness

Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), pelvic pain

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Aggrastat